New Antithrombotic Drugs

This publication has 181 references indexed in Scilit:

• RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome
  European Heart Journal, 2011
• Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI
  JAMA, 2010
• Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease
  European Heart Journal, 2010
• Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases
  British Journal of Pharmacology, 2010
• Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists
  European Heart Journal, 2009
• Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
  The Lancet, 2009
• Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion–diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study
  The Lancet Neurology, 2008
• Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke
  New England Journal of Medicine, 2008
• First-in-Human Experience of an Antidote-Controlled Anticoagulant Using RNA Aptamer Technology
  Circulation, 2006
• Destabilase, the novel ϵ-(??-Glu)-Lys isopeptidase with thrombolytic activity
  Blood Coagulation & Fibrinolysis, 1991